PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Until recently, systemic chemotherapy was the only option for treating bladder cancer and outcomes remained dismal. After a long gap of no progress for 40 years, immuno-therapy with checkpoint inhibitors (PDL1 and PD1) has revolutionized the treatment paradigm of bladder cancer, with five approved agents to treat platinum-refractory bladder cancer since the first approval of atezolizumab in May 2016. METHODS: This review summarizes the most recent data on approved checkpoint inhibitors currently used in management of advanced bladder cancer. Early- and late-phase trials of the five checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab) in advanced bladder cancer are reviewed in detail. This review also describes the potential application of PD1/PDL1 inhibitors in adjuvant and neoadjuvant settings and non-muscle-invasive bladder cancer, as well as with radiation in muscle-invasive bladder cancer treatment. The role of PDL1 and tumor-mutation burden and clinical considerations in choosing a particular immunotherapy are also discussed. RESULTS: The approved checkpoint inhibitors (PD1 and PDL1 inhibitors) have similar efficacy and safety profiles in metastatic platinum-refractory bladder cancer, but they vary in dose and frequency and cost burden. However, only pembrolizumab has shown superiority over standard chemotherapy in a randomized Phase III setting so far. In addition, in the first-line setting for cisplatin-ineligible patients, both pembrolizumab and atezolizumab are US Food and Drug Administration-approved and well tolerated. There is a lack of consensus on the utility of testing for PDL1 as a predictive biomarker, as patients with no PDL1 expression also derive some clinical benefit. Tumor-mutation burden is another predictive biomarker, but needs further validation. CONCLUSION: Immunotherapy has offered a glimmer of hope to patients with bladder cancer. The current landscape is rapidly evolving, with novel immunotherapy-combination trials to improve outcomes further and evaluate predictive biomarkers to help identify patients most likely to benefit from such therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, PD-L1-negative tumors can still occasionally respond to anti-PD-1 therapy, and high PD-L1 expression, although correlative, is by no means sufficient for generating a response following anti-PD-1 therapy, indicating that other factors are involved in determining response and nonresponse to ICIs (80)(81)(82).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Bladder tumors have the third-highest rate of somatic mutations and are highly antigenic.(16) Additionally, therapeutic agents can be placed in direct contact with the tumor through intravesical administration, allowing a high concentration of the agent to be delivered with limited systemic exposure.”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 1×
“17–19 It is also possible to monitor treatment response through direct surveillance of the tumor and related cells and biomarkers.”
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“The presence of certain bacteria in human microbiota (eg, commensal Bifidobacterium and Akkermansia muciniphila) is associated with an active immunoresponse when they are present in patients being treated with immunocheckpoint inhibitors.(47,48) Absence of these activating microbiota may result in an ineffective respo…”
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 4×
“The IMvigor 210 clinical study was a Phase II, multicenter, open-label trial of atezolizumab with two cohorts and provided the evidence for the FDA-approval decisions.(19,32) Cohort 1 included advanced UC patients who were ineligible O nc oT ar ge ts a nd T he ra py d ow nl oa de d fr om h ttp s: //w w w .”
InfluentialPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395 · cited 2×
“4%).(26) Treatment-related AEs occurred in 60.”
Cited by
Items 101–144 of 144
Hasaligil, A., Munro, V., Strunz, T., Wang-Silvanto, J., Milloy, N., Unsworth, M., & Santis, M. D. (2025) · Future Oncology · doi:10.1080/14796694.2024.2445498 · Cited by 2
“The treatment landscape has also evolved significantly with the approval of several programmed cell death protein 1/ligand 1 (PD-1/L1) inhibitors, of which pembrolizumab and atezolizumab are recommended as alternative 1 L therapies for platinum-ineligible patients [14–16].”
Wang, B. H., Davis, L. E., Nandwana, D., Siva, J., Maina, E., Weight, C. J., Haywood, S., Campbell, S. C., Campbell, R., Sindhani, M., et al. (2026) · European Urology Open Science · doi:10.1016/j.euros.2026.02.002 · Cited by 2
“Second, the approval of PD-1 inhibitors as adjuvant therapy for locally advanced or metastatic urothelial carcinoma has expanded systemic treat-ment options, with many studies including patients with UTUC [15–17].”
Black, P. C., & Eigl, B. J. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02763-z · Cited by 2
“PD-1-targeted therapies have proven activity in more advanced forms of urothelial cancer [25].”
BackgroundEstablish TIIC signature score based the machine learning fusion in bladder cancer
Zeng, X., Lu, Z., Dai, C., Su, H., Liu, Z., & Cheng, S. (2024) · Discover Oncology · doi:10.1007/s12672-024-01187-7 · Cited by 5
“In recent years, immunotherapy has garnered attention as a novel treatment strategy, particularly PD-1/PD-L1 inhibitors showing promise in the treatment of advanced BLCA [47].”
Zhu, L., Xiao, F., Hou, Y. X., Huang, S., Xu, Y., Guo, X., Dong, X., Xu, C., Zhang, X., & Gu, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1491808 · Cited by 4
Mikhaylenko, D. S., Сергиенко, С. А., Zaborskii, I. N., Saflullin, K. N., Serebryany, S. A., Safronova, N. Y., Nemtsova, M. V., Каприн, А. Д., & Alekseev, B. Y. (2018) · Cancer Urology · doi:10.17650/1726-9776-2018-14-4-124-138 · Cited by 2
Maintenance Avelumab in Metastatic Bladder Cancer as a Step Towards Sequencing Immunotherapy
Samaha, H., Samaha, R., Sarkis, J., & Kattan, J. G. (2021) · Immunotherapy · doi:10.2217/imt-2020-0261 · Cited by 2
Walach, M. T., Burger, R., Brumm, F., Nitschke, K., Wessels, F., Nuhn, P., Worst, T. S., von Hardenberg, J., Grüne, B., & Jarczyk, J. (2025) · World Journal of Urology · doi:10.1007/s00345-025-05452-4 · Cited by 1
“IO is associated with manageable adverse events and is generally well tolerated [ 3].”
Li, N., Gao, Q., Jia, H., Xue, G., Zhou, Y., Wang, S., Ma, S., Hu, B., Zhao, Z., Chen, S., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci198270 · Cited by 3
Corneal transplant rejection after treatment with pembrolizumab: report of two cases
Boehm, B. A., Sahawneh, H., & Sheng, I. Y. F. (2026) · Journal of Cataract & Refractive Surgery Online Case Reports · doi:10.1097/j.jcro.0000000000000244 · Cited by 1
Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update
Lee, A. J. X., Waterhouse, J., & Linch, M. D. (2020) · EMJ Oncology · doi:10.33590/emj/20-00044 · Cited by 1
Liu, Y., Liu, Y., Liu, Y., Chen, X., & Zhang, M. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01313-8 · Cited by 1
“Multiple studies have demonstrated that inhibiting the combination of PD-1 and PD-L1 can effectively improve the prognosis of various solid tumors and hematological malignancies [40, 41].”
Background(2023) · European Journal of Gynaecological Oncology · doi:10.22514/ejgo.2023.096 · Cited by 1
Liang, W., Wang, Z., Huang, Z., Huang, Y., Li, C., Liang, Y., Huang, M., Zhang, D., & Li, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1430673 · Cited by 1
Upper Tract Urothelial Carcinoma
Calvaresi, A. E., Bagley, D. H., & Smentkowski, K. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-52021-2_19 · Cited by 1
An overview on precision therapy in bladder cancer
Sayed, A., Munir, M., Eweis, N., Wael, D., Shazly, O., Awad, A. K., Elbadawy, M. A., & Eissa, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1801346
Comparative pharmacoeconomic analysis of biologicals used for metastatic urothelial carcinoma
Tolkushin, A. G., Лучинин, Е. А., & Hołownia-Voloskova, M. E. (2021) · Cancer Urology · doi:10.17650/1726-9776-2021-17-2-112-127
A Mathematical Model for Controlling Exchanged Spinor Waves between Hemoglobin, Tumor and T-Cells
Fioranelli, M., Sepehri, A., Roccia, M. G., Beesham, A., & Flavin, D. (2021) · Mathematics · doi:10.3390/math9243310
Upper Tract Urothelial Carcinoma
Rudnick, B., Hubosky, S. G., HooKim, K., Bagley, D. H., Rodríguez‐Monsalve, M., Keller, E. X., Coninck, V. D., Traxer, O., Grasso, M., Sharma, N., et al. (2021) · Springer eBooks · doi:10.1007/978-3-030-82351-1_6
The Role of Immunotherapy in Renal Cell Carcinoma
Doppalapudi, S. K., Kaldany, A., Lichtbroun, B., & Singer, E. A. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_232-1
Single Drug Therapy of PD-1/PD-L1 Checkpoint Inhibitors for Advanced Urothelial Bladder Cancer
Ge, H., Lee, H., Liu, Y., & Sun, R. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v36i.5576 · Cited by 1
“The only options up until recently were carboplatin-based regimens, and clinical outcomes did not significantly improve [1].”
BackgroundWang, Z., Bi, H., Wang, Y. D., Liu, Q., Shao, B., Li, C. Q., Fu, C., Fu, S., Shan, G. Y., Chen, A., et al. (2023) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2023.10.010
Sun, W., Peng, J., Pan, S., Wang, C., & Yuan, M. (2024) · annals of urologic oncology · doi:10.32948/auo.2024.02.10
Pouliasi, F., Salamaliki, C., Kanaloupitis, S., Verigou, E., Liolis, E., Koutras, A. K., Makatsoris, T., Kalofonos, C. P., Liossis, S. C., & Solomou, E. E. (2024) · Applied Sciences · doi:10.3390/app14124990
“…cell carcinoma (RCC), hepatocellular carcinoma, metastatic small-cell lung cancer (SCLC), colorectal carcinoma, and Hodgkin’s lymphoma [8,11,19–22], whereas alternative potential checkpoint targets in immune cells are under investigation, such as lymphocyte activation gene-3 (LAG-3) that…”
BackgroundExpression of PD-L1 (DAKO 28-8) in Urothelial Carcinoma of Urinary Bladder
Azmat, H., Masood, A., Chaudry, S. S., Mushir, S. I., Sheikh, A. K., & Riaz, S. K. (2024) · Asian Pacific Journal of Cancer Biology · doi:10.31557/apjcb.2024.9.2.179-182
Immunotherapy for Renal Cell Carcinoma
Doppalapudi, S. K., Kaldany, A., Lichtbroun, B., & Singer, E. A. (2024) · Springer eBooks · doi:10.1007/978-3-030-80962-1_232-2
Crossman, B. E., Harmon, R. L., Iida, M., Adams, J. M., Lin, C. Y., Glitchev, C. E., Juang, T. D., Kerr, S. C., Alexandridis, R. A., Hyun, M., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1579214 · Cited by 1
“While PD-L1 is currently the only biomarker to select patients eligible to receive pembrolizumab, clinical trial data has shown that improvement in pathologic complete response is seen regardless of PD-L1 status (47).”
Zhang, Z., Zhong, J., Iqbal, M. S., Zeng, Z., & Duan, X. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102060
“…clinical trials involving immune checkpoint inhibitors for bladder cancer are underway, showing considerable promise in improving and maintaining the quality of life for bladder cancer patients, particularly those with severe comorbidities who are unable to undergo standard treatments [31,32].”
Immunotherapy for Renal Cell Carcinoma
Doppalapudi, S. K., Kaldany, A., Lichtbroun, B., & Singer, E. A. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_232
Zhang, Z., Yu, Y., Zhang, Z., Li, D., Liang, Z., Wang, L., Chen, Y., Liang, Y., & Niu, H. (2024) · Figshare · doi:10.6084/m9.figshare.26645092
Zhang, Z., Yu, Y., Zhang, P., Ma, G., Zhang, M., Liang, Y., Jiao, W., & Niu, H. (2021) · Figshare · doi:10.6084/m9.figshare.14480018
Zhang, Z., Yu, Y., Zhang, Z., Li, D., Liang, Z., Wang, L., Chen, Y., Liang, Y., & Niu, H. (2024) · Figshare · doi:10.6084/m9.figshare.26645086
Zhang, Z., Yu, Y., Zhang, Z., Li, D., Liang, Z., Wang, L., Chen, Y., Liang, Y., & Niu, H. (2024) · Figshare · doi:10.6084/m9.figshare.24633468
Zhang, Z., Yu, Y., Zhang, Z., Li, D., Liang, Z., Wang, L., Chen, Y., Liang, Y., & Niu, H. (2024) · Figshare · doi:10.6084/m9.figshare.26645098
Zhang, Z., Yu, Y., Zhang, Z., Li, D., Liang, Z., Wang, L., Chen, Y., Liang, Y., & Niu, H. (2023) · Figshare · doi:10.6084/m9.figshare.24633325
Zhang, Z., Yu, Y., Zhang, Z., Li, D., Liang, Z., Wang, L., Chen, Y., Liang, Y., & Niu, H. (2024) · Figshare · doi:10.6084/m9.figshare.26645089
Zhang, Z., Yu, Y., Zhang, Z., Li, D., Liang, Z., Wang, L., Chen, Y., Liang, Y., & Niu, H. (2024) · Figshare · doi:10.6084/m9.figshare.26645083
Zhang, Z., Yu, Y., Zhang, Z., Li, D., Liang, Z., Wang, L., Chen, Y., Liang, Y., & Niu, H. (2024) · Figshare · doi:10.6084/m9.figshare.26645077
Morsch, R., Rose, M., Maurer, A., Cassataro, M. A., Braunschweig, T., Knüchel, R., Vögeli, T.-A., Ecke, T., Eckstein, M., Weyerer, V., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12004641
Zhang, Z., Yu, Y., Zhang, Z., Li, D., Liang, Z., Wang, L., Chen, Y., Liang, Y., & Niu, H. (2024) · Figshare · doi:10.6084/m9.figshare.26645080
Morsch, R., Rose, M., Maurer, A., Cassataro, M. A., Braunschweig, T., Knüchel, R., Vögeli, T.-A., Ecke, T., Eckstein, M., Weyerer, V., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12004647
Camacho, L., Cacho-Navas, C., Agüero, J., Batmunkh, B., Gracia, J. M., Sullivan, K. O., Rementeria, M., Miles, J., Gumuzio, J., Aguirre, F., et al. (2026) · medRxiv · doi:10.64898/2026.09.01.26361904
de Camargo, J. A., Lee, M. C., de Souza, M. M., Silva, L. P., Boas, G. C. V., da Silva, K. S., Mioshi, C. M., Pimenta, R., Candido, P., da Silva, I. A., et al. (2026) · IUBMB Life · doi:10.1002/iub.70130
Metadata
- Authors
- Stenehjem, D., Tran, D., Nkrumah, M., & Gupta, S.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Gupta, Shilpa
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2018-09
- Volume
- Volume 11
- Pages
- 5973-5989
- ISSN
- 1178-6930 (ISSN-L)
- PMC
- PMC6157986
- OpenAlex
- W2890398072
- Cited by
- 144
- References
- 47
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 26 · 2023: 20 · 2022: 19 · 2021: 25 · 2020: 25 · 2019: 10 · 2018: 2
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoTargets and Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Keywords
- PD-1 inhibitors, PD-L1 inhibitors, bladder urothelial carcinoma, immune checkpoint inhibitors, pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, adjuvant immunotherapy, neoadjuvant immunotherapy, non-muscle-invasive bladder cancer, muscle-invasive bladder cancer, radiotherapy, tumor mutational burden, predictive biomarkers, combination immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.